Endocrine Abstracts

Androgens are considered beneficial for athletic performance by potent anabolic effects on muscle mass and bone tissue. Testosterone also increases circulating hemoglobin, which will enhance oxygen uptake. Furthermore, androgens may exert behavioral and psychological effects of importance for athletic performance including increased mental drive and competitiveness. Studies in men have shown clear relationships with both exogenous and endogenous circulating testosterone to mus...

Objectives: Polycystic ovary syndrome (PCOS) and thyroid disorders have separately been linked to adverse pregnancy and neonatal outcomes. Even small variations in thyroid function within the normal range may influence fetal growth. Previous data have shown that metformin-treatment of pregnant women with PCOS reduced late miscarriages and preterm births, and resulted in less decrease of fT4 compared to placebo. Moreover, metformin exposure in utero altered the offspring anthro...

Background: The prevalence of reproductive disturbances in women with Type 1 Diabetes Mellitus (T1DM) is high compared to the general population. One reason might be higher prevalence of Polycystic ovary syndrome (PCOS) in T1DM. In Sweden, with a high incidence of T1DM, the prevalence of PCOS in women with T1DM is not known. Neither is the T1DM-PCOS pathophysiology.Aim: The aim of this cross-sectional study was to investigate the prevalence of PCOS in a ...

Introduction: Polycystic ovary syndrome (PCOS) is the leading cause of female infertility and is associated with high degree of comorbidities including type 2 diabetes and endometrial cancer. Hyperandrogenemia is a hallmark of PCOS and contributes to endometrial-related dysfunctions, including implantation failure and miscarriage. Whether cellular heterogeneity contributes to the functioning of the endometrium is not previously studied. Therefore, the aim is to reveal cell-typ...

Introduction: There is a need for well tolerated and effective nonhormonal therapies for vasomotor symptoms (VMS) associated with menopause. Fezolinetant is a nonhormonal, selective neurokinin 3 receptor antagonist that is approved for the treatment of moderate-to-severe VMS associated with menopause.Objective: To assess how early a response to fezolinetant in frequency and severity of moderate-to-severe VMS was observed in the 24-week placebo-controlled...

Women with polycystic ovary syndrome (PCOS) suffer from reduced fertility linked to implantation failure and miscarriage, as well as endometrial cancer, all associated with endometrial dysfunction. We hypothesize that cell-type-specific endometrial dysfunction in insulin-resistant and hyperandrogenic women with PCOS contributes to their endometrial dysfunction and that treatment aimed at improving insulin sensitivity and decreasing androgen excess has the potential to reverse ...

Introduction: First-line treatment for congenital adrenal hyperplasia (CAH) is hydrocortisone1. When adequate control is not achieved, prednisolone (or its prodrug prednisone) are often used. However, there has been no formal comparison of disease control in CAH comparing prednis(ol)one vs hydrocortisone and patients are often on a glucocorticoid dose that exceeds the guideline recommended dose of hydrocortisone (≤25 mg/day)1,2. We report an interim...

Background: Management of CAH involves replacing cortisol deficiency and reducing raised adrenal androgens, however the supraphysiological glucocorticoid doses often required to treat hyperandrogenism are associated with poor long-term health outcomes. Modified-release hydrocortisone (MRHC) capsules, Efmody, replicate cortisol diurnal rhythm and improve control of CAH compared to standard glucocorticoid therapy. Here we report changes in glucocorticoid daily dose and 9am 17-hy...

Background: Adrenal crisis is the leading cause of excess mortality in patients with CAH1. Retrospective studies report an adrenal crisis incidence of 5-10/100 patient years (PY), with mortality 0.5/100 PY2. Modified-release hydrocortisone (MRHC) capsules, (Efmody), replicate cortisol diurnal rhythm and improve androgen control in CAH compared to standard glucocorticoid therapy2. Here, we report the incidence of adrenal crisis in CAH patients f...

Background: Patients with congenital adrenal hyperplasia (CAH) due to classic 21-hydroxylase deficiency have poor health outcomes. We compared disease control in CAH adults treated with modified release hydrocortisone (MRHC, Chronocort®, Diurnal Ltd) versus standard glucocorticoid (GC).Methods: 6-month, Phase 3 study in 122 patients randomised to either MRHC twice daily or standard GC followed by safety extension study on MRHC. Patients had 24-hr 17...